• 1
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231.
  • 2
    Neumann AU, Lam NP, Dehari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282:103107.
  • 3
    Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon-alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366371.
  • 4
    Neumann AU, Lam NP, Dehari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:2835.
  • 5
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis treated with standard and peginterferon alfa-2a. Hepatology 2001; 120:14381447.
  • 6
    Layden JE, Layden TJ. How can mathematics help us understand HCV? Gastroenterology 2001; 120:15461549.
  • 7
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958965.
  • 8
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5:431435.
  • 9
    Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994; 9:587591.
  • 10
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:10931102.
  • 11
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:2130.
  • 12
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al. Adherence to combination therapy enhances sustained response in genotype -1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123:10611069.
  • 13
    Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen, Sette H, et al. Peg-interferon alfa-2a (40KD)(Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examing the effect of duration of treatment and ribavirin dose [Abstract]. J Hepatol 2002; 37:536A.
  • 14
    Rebetol summary of product characteristics. The European Agency for the Evaluation of Medicinal Products. Available at:
  • 15
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a U.S. multicenter randomized controlled study. N Engl J Med 1998; 339:14851492.
  • 16
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432.
  • 17
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321:15011506.
  • 18
    Fukutomi T, Nakamuta M, Fukutomi M, Iwao M, Watanabe H, Hiroshige K, Tanabe Y, et al. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001; 34:100107.
  • 19
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33:419423.
  • 20
    Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9:340345.
  • 21
    Nolte FS, Fried MW, Shiffman ML, Ferreira-Gonzalez A, Garrett CT, Schiff ER, Polyak SJ, Gretch DR. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001; 39:40054012.
  • 22
    Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. J Viral Hepat 1999; 6:145150.
  • 23
    Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, Perrillo RP, et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19:13371341.
  • 24
    Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:11311137.
  • 25
    Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000; 95:29282935.
    Direct Link:
  • 26
    Everson G. Maintenance interferon for chronic hepatitis C: more issues than answers. Hepatology 2000; 32:436438.
  • 27
    Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27:201205.
  • 28
    Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. This month from the NIH: HALT-C study. Hepatology 2002; 36:792793.
  • 29
    National Institutes of Health Consensus Development Conference Statement: management of Hepatitis C: 2002. Hepatology 2002; 36(Suppl):S320.
  • 30
    Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36(Suppl):S145S151.
  • 31
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr, Häussinger D, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975982.